The 2023 AACC (now renamed to Association for Diagnostics & Laboratory Medicine, abbreviated to ADLM) was held from July 23rd to 27th at Anaheim Convention Center, Anaheim, California, USA. Sansure Biotech, the world’s leading in-vitro diagnostic solution provider, made an impressive appearance at the AACC exhibition to showcase their exceptional products.
In this article, we’ll explore Sansure Biotech’s presentation at AACC 2023, highlighting their comprehensive range of offerings, which are all designed to enhance accuracy and efficiency in disease diagnostics.
The AACC exhibition serves as a significant platform for industry leaders, healthcare professionals, and researchers to exchange ideas, knowledge, and advancements in the field of clinical chemistry and laboratory medicine.
This year, AACC provides information on cutting-edge technology featuring 800+ exhibitors and 200+ new products, which meets various clinical needs to stay ahead of changes in the field. Sansure Biotech, a key player in the industry, aligns perfectly with the expo’s spirit, as the company continuously strives for excellence in its diagnostic solutions.
Sansure Biotech is a pioneering provider of in vitro diagnostic solutions, revolutionizing the field with its innovative gene technology. The company seamlessly integrates diagnostic reagents and instruments to offer comprehensive genetic testing solutions. Through tireless research and development efforts, they have emerged as a forerunner in the field.
The company’s advantage lies in its development of advanced core technologies. By offering types of diagnostic technology, Sansure Biotech ensures a comprehensive range of solutions for various diagnostic needs.
From high-end laboratories in large hospitals to primary medical institutions at all levels, Sansure Biotech is making gene technology accessible to a wide range of healthcare settings, expanding the reach of gene technology from a few specific fields to all-encompassing scenarios.
As Sansure Biotech continues to push the boundaries of genetic technology, its dedication to innovation, service, and accessibility remains unwavering. With its cutting-edge solutions, the company is relentlessly contributing to the advancements in healthcare for the benefit of all.
Sansure Biotech’s Exhibits at AACC 2023
At AACC 2023, Sansure showcased its comprehensive diagnostic solutions. Let’s take a closer look at these outstanding exhibits.
One of the highlights of Sansure Biotech’s exhibits at AACC 2023 was their iPonatic III–Portable Molecular Workstation stood out as a new addition to the iPonatic series, boasting advanced capabilities that optimize molecular diagnostics.
Its fully automated rapid testing process and “sample-in-result-out” system provide test results in just 15–45 minutes. Moreover, the workstation’s rich and extendable testing menu meets the demands of testing various pathogens across different scenarios.
The iPonatic III brings efficiency and accuracy to the forefront while empowering healthcare professionals to make timely and informed decisions for better patient care.
Sansure Biotech showcased its Q-POC, a rapid and portable molecular diagnostic device at the exhibition. Q-POC supports ultra-multiple target detection, providing results within 25 minutes.
It offers various molecular diagnostic tests, including complex infectious diseases, drug resistance gene screening, personalized drug use gene testing, and early cancer screening, aiming to develop multiple tests and make precision medicine solutions more accessible to the public.
Surelite 8 made its debut at this year’s AACC exhibition. Weighing approximately 12kg, Surelite 8 is an ultra-compact POCT platform. It boasts simple operation, reliable performance, offering a wide range of testing options.
Besides showing their high-tech medical instruments, Sansure held various activities at AACC. Their professional team conducted a series of in-booth presentations, which featured iPonatic III for Point-of-Care Testing, Surelite for Immunoassay Testing, and Q-POC for Rapid Multiplex PCR Testing.
Another interesting activity was the alcohol tolerance gene test, which allowed participants to understand their own alcohol tolerance levels and receive healthy drinking advice. This activity garnered significant excitement, with more than 100 samples collected, creating a lively atmosphere.
Sansure also delivered a speech on “How Leading Labs Are Diversifying Their Product Offerings to Address Reductions in COVID-19 Testing.”
They shared valuable insights on how laboratories are actively leveraging their strong testing capacity and underutilized equipment acquired during the pandemic to generate new revenue streams and adapt to changing market demands.
Although the AACC exhibition has ended, Sansure will continue to provide highly accessible products and solutions to the world. With a focus on transformative diagnostic excellence, Sansure Biotech envisions a future where accurate and timely diagnostics play a pivotal role in improving patient outcomes worldwide.
The company aims to develop more affordable and user-friendly gene technology, products, and services, contributing to the creation of a healthier and more inclusive world.